ArticleThe Journal of infectious diseases2020
Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.
Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 3 syntheses or guidelines pooled it, 295 citations in OpenAlex.
- Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.Vaccine · 2021Guideline
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- COVID 19 repercussions in ophthalmology: a narrative review.Sao Paulo medical journal = Revista paulista de medicinaPooled it
- When Is Social Value Proportionate to Research Risks?Bioethics · 2026Article
- Ethical Frameworks for Conducting Social Challenge Studies.Journal of empirical research on human research ethics : JERHRE · 2026Review
- Article
- Article
- Vaccine failure mode determines population-level impact of vaccination campaigns during epidemics.Journal of the Royal Society, Interface · 2025Article
- Article
- Positive and negative factors of parents vaccinating their children against COVID-19: An umbrella review.Preventive medicine reports · 2024Review
- Ethical acceptability of human challenge trials: Consultation with the US public and with research personnel.PloS one · 2024Article
- Article
- Human Challenge Studies with Coronaviruses Old and New.Current topics in microbiology and immunology · 2024Review
- Research integrity during the COVID-19 pandemic: Perspectives of health science researchers at an Academic Health Science Center.Accountability in research · 2023Article
- These volunteers want to be infected with disease to aid research - will their altruism help?Nature · 2023Article
- Novel Influenza Vaccines: From Research and Development (R&D) Challenges to Regulatory Responses.Vaccines · 2023Review
- Some principles for using epidemiologic study results to parameterize transmission models.medRxiv : the preprint server for health sciences · 2023Article
- First Do No Harm? Modeling Risks and Benefits of Challenge Trials for Hepatitis C Vaccine Development.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Key ethical issues encountered during COVID-19 research: a thematic analysis of perspectives from South African research ethics committees.BMC medical ethics · 2023Article
- Risk, benefit, and social value in Covid-19 human challenge studies: pandemic decision making in historical context.Monash bioethics review · 2022Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, if they have a high baseline risk of natural infection, and if during the trial they receive frequent monitoring and, following any infection, the best available care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.